Venus Remedies Gets Argentina Nod for Key Antibiotic

India-based Venus Remedies has secured marketing approval in Argentina for its antibiotic drug used to treat serious bacterial infections, marking another step in the company’s global expansion strategy.

The approval allows the pharmaceutical company to commercialize its antibiotic product in the South American nation, strengthening its footprint in the Latin American healthcare market.

The approved drug, Meropenem + Sulbactam, is designed to treat a wide range of bacterial infections, including complicated infections caused by resistant bacteria. The company said the approval was granted by Argentina’s drug regulatory authority after a detailed review process.

Speaking on the development, Venus Remedies President and Director Saransh Chaudhary said, “This approval is a testament to our commitment to delivering high-quality and innovative antimicrobial therapies across global markets.”

Also Read: The Future of MedTech in India: Meeting Tier-2 and Tier-3 Needs

The company believes the Argentine market holds strong growth potential due to rising demand for advanced anti-infective treatments. With antimicrobial resistance becoming a growing healthcare concern worldwide, the approval is expected to help the company expand access to effective treatment options in the region.

The latest approval also aligns with the company’s long-term strategy of increasing its presence in regulated and semi-regulated international markets. Over the years, Venus Remedies has focused heavily on strengthening its antibiotics portfolio while expanding exports across several countries.

The company added that the approval further reinforces its position in the global injectable antibiotics segment. Argentina now joins the list of international markets where the company has received approvals for its antimicrobial products, helping boost its overseas business prospects.

Aditi K. Chaudhary, President, International Business, Venus Remedies Limited, said, “Securing this marketing authorization in Argentina is a strategically important milestone in our Latin America expansion journey.”